Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Telisotuzumab Vedotin · Emrelis, ABBV-399

Antibody-drug conjugate · Cytotoxic, directed at c-Met (MET) · developed by Abbvie

Approved FDA, May 2025

ABBV Developer

1 Registered trials

What is Telisotuzumab Vedotin?

Telisotuzumab vedotin-tllv is a c-Met-directed antibody drug conjugate containing MMAE, a microtubule-disrupting agent. The antibody binds c-Met on tumor cells, undergoes internalization, and releases MMAE intracellularly to disrupt microtubules, causing cell cycle arrest and apoptosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Emrelis, ABBV-399, ABT-399, PR-1420682
Drug type: Antibody-drug conjugate
Targets: c-Met (MET)
Mechanism: Cytotoxic, directed at c-Met (MET)
Pathways: microtubule disruption, cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: Abbvie Inc (ABBV)
FDA status: Approved as Emrelis (May 14, 2025), BLA761384 · FDA label
UNII: 976X9VXC3Z

✅ FDA-approved uses

Locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression

From the indications section of the FDA label (version of May 25, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04928846	Phase 3	Non Small Cell Lung Cancer	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Small Cell Lung Cancer

Other drugs acting on MET

Tepotinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 FPI-2053 Phase 1 Sitravatinib Phase 3 Telisotuzumab Adizutecan Phase 3 Vebreltinib Phase 1/2

More from Abbvie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1 ABBV-438 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Telisotuzumab Vedotin

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z